恒瑞医药:海曲泊帕乙醇胺片药品上市许可申请获国家药监局受理

格隆汇
Aug 18, 2025

恒瑞医药(600276.SH)公告称,公司收到国家药监局下发的《受理通知书》,公司海曲泊帕乙醇胺片的药品上市许可申请获国家药监局受理,适应症为用于化疗为主的抗肿瘤治疗所致血小板减少症成人患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10